Jeena Sikho Lifecare Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Net profit of Jeena Sikho Lifecare rose 121.02% to Rs 58.79 crore in the quarter ended September 2025 as against Rs 26.60 crore during the previous quarter ended September 2024. Sales rose 66.40% to Rs 189.85 crore in the quarter ended September 2025 as against Rs 114.09 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

Jeena Sikho Lifecare will hold a meeting of the Board of Directors of the Company on 6 November 2025.

Powered by Capital Market - Live News

Jeena Sikho Lifecare has commenced operations of its 230-bed hospital at Raigad District, Maharashtra with effect from 23 September 2025.

Powered by Capital Market - Live News

Jeena Sikho Lifecare has received approval for conducting a clinical trial on the following products:

1. Anti-Diabetes Efficacy of SDM02 Tablets - Pre-clinical study conducted at MIET, Meerut, on streptozotocin-induced diabetic rats. The tablets were found effective with no mortality or adverse effects at the tested dose.

2. Shuddhi XS Syrup - Clinical trial on 60 subjects with constipation conducted at CCFT Laboratories, Meerut. 92% reported relief in constipation and abdominal pain, with no adverse events.

3. Petshuddhi Churna - Retrospective clinical study on 100 patient records conducted at Hospital & Institute of Integrated Medical Sciences, Meerut. Significant improvement observed in bowel movement, stool consistency, and abdominal discomfort. No adverse events reported.

4. Shuddhi Dr. B P Care Tablets - Clinical trial on 60 hypertensive patients conducted at CCFT Laboratories, Meerut. Significant reduction in systolic and diastolic blood pressure and heart rate was observed within 2-3 hours and sustained for 6 hours. No adverse events reported.

Powered by Capital Market - Live News